Drug-coated balloons (DCBs) are widely used in clinical practice; however, the clinical impact of differences between DCB platforms, including paclitaxel dose, remains uncertain. This study compared the clinical efficacy and safety of low-dose (LD) versus regular-dose (RD) paclitaxel-coated balloons (PCBs) for de novo coronary lesions using data from the ALLIANCE registry, a prospective, multicenter, all-comers study. Patients treated with an LD-PCB (AGENT) or RD-PCB (SeQuent Please Neo) were compared using propensity score matching at a target LD-to-RD ratio of 2:1. The primary endpoint was 1-year target lesion failure (TLF), defined as a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization (cd-TLR). Among 1,568 patients included in this analysis, propensity score matching yielded 784 patients in the LD-PCB group and 419 in the RD-PCB group. At 1 year, the incidence of TLF was 5.1
Mechanical circulatory support (MCS) practice for cardiogenic shock may vary with institutional resources and operator experience, but data from Japanese interventional cardiologists are limited. We conducted an anonymous cross-sectional survey of 720 members of 83 Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT)-certified or affiliated training hospitals in the CVIT Kyushu–Okinawa Chapter (September–October 2025); 536 returned questionnaires (74.4
